Published in Clin Pharmacol Ther on February 01, 2007
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov (2010) 1.08
Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity. PLoS Comput Biol (2013) 1.02
Teaching the fundamentals of biological data integration using classroom games. PLoS Comput Biol (2012) 0.87
Successes achieved and challenges ahead in translating biomarkers into clinical applications. AAPS J (2010) 0.84
The clinical pharmacogeneticist: an emerging regulatory scientist at the US Food and Drug Administration. Hum Genomics (2010) 0.80
The transformation in biomarker detection and management of drug-induced liver injury. Liver Int (2017) 0.75
Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther (2012) 3.22
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 3.18
A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn (2001) 3.10
Biomarkers for smoking cessation. Clin Pharmacol Ther (2013) 1.15
Balantidium coli-induced pulmonary haemorrhage with iron deficiency. S Afr Med J (2010) 1.06
Assessing sources of inconsistencies in genotypes and their effects on genome-wide association studies with HapMap samples. Pharmacogenomics J (2010) 1.00
Variability in GWAS analysis: the impact of genotype calling algorithm inconsistencies. Pharmacogenomics J (2010) 1.00
Modulation of macrophage lysosomal pH by Mycobacterium tuberculosis-derived proteins. Infect Immun (1988) 0.94
Assessment of variability in GWAS with CRLMM genotyping algorithm on WTCCC coronary artery disease. Pharmacogenomics J (2010) 0.93
The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Clin Pharmacol Ther (2010) 0.91
Batch effects in the BRLMM genotype calling algorithm influence GWAS results for the Affymetrix 500K array. Pharmacogenomics J (2010) 0.88
Inhibition of mitogenesis induced by phytohemagglutinin and Lens culinaris lectin in adherent-cell supernatants treated with protein extract of Mycobacterium tuberculosis. Infect Immun (1986) 0.87
In situ synthesis of oligonucleotide arrays by using surface tension. J Am Chem Soc (2001) 0.86
Evaluation of phagolysosome fusion in acridine orange stained macrophages infected with Histoplasma capsulatum. Clin Exp Immunol (1989) 0.86
The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J (2005) 0.85
Catalyzing the Critical Path Initiative: FDA's progress in drug development activities. Clin Pharmacol Ther (2015) 0.79
Study of Fc gamma murine macrophage receptors (Fc gamma R) in the internalization of Histoplasma capsulatum yeasts. Arch Med Res (1995) 0.78
The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther (2007) 0.77
Porphyrin content of the cysticercus of Taenia solium. J Parasitol (1986) 0.76
'Oil globules' in Duchenne muscular dystrophy--history, demonstration, and metabolic significance. Med Hypotheses (1994) 0.76
Analysis of porphyrins and enzymes in porphyrin synthesis in Taenia solium cysticercus from man and pig. Mol Biochem Parasitol (1987) 0.76
Intracellular lipid in pseudohypertrophic muscular dystrophy tissue culture. J Indiana State Med Assoc (1979) 0.75
Duchenne's muscular dystrophy: a tissue culture perspective. Indiana Med (1984) 0.75
The dystrophin connection--ATP? Med Hypotheses (1992) 0.75
Automated detection of prevalent mutations in BRCA1 and BRCA2 genes, using a fluorogenic PCR allelic discrimination assay. Genet Test (1999) 0.75
5' Nuclease assays for the loci CCR5-+/Delta32, CCR2-V64I, and SDF1-G801A related to pathogenesis of AIDS. Clin Chem (2000) 0.75
Pharmacogenetics: from bench to bedside. Clin Chem Lab Med (2003) 0.75
Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J (2006) 0.75